What Is KPV? A Complete Guide to the α-MSH Anti-Inflammatory Tripeptide

KPV occupies an unusual position in the research peptide landscape. It's one of the shortest bioactive peptides in current research use — just three amino acids — yet it retains the full anti-inflammatory activity of a 13-amino-acid parent hormone (α-melanocyte-stimulating hormone) while eliminating that hormone's most limiting side effect (pigmentation induction). This combination of extreme structural simplicity and preserved biological function has made KPV a reference tripeptide across inflammatory disease models for nearly four decades.

This guide covers what KPV is, how it was discovered, how it functions mechanistically, and where it fits within the current research peptide landscape — including the significant 2026 regulatory developments that have changed its status. For research groups selecting compounds for inflammatory bowel disease, dermatological inflammation, or immunomodulation research designs, understanding KPV's specific properties determines when it's the appropriate research tool.

Our KPV research peptide is available at ≥99% HPLC purity with mass-spec-verified identity and batch-specific certificates of analysis. Every vial is supplied strictly for laboratory research use only. KPV is investigational — not approved by Health Canada or the FDA for human therapeutic use — though regulatory review activity in 2026 has begun to change the compound's compounding-pharmacy access status in the United States.

The Core Definition

KPV is a three-amino-acid peptide (lysine-proline-valine) that corresponds to the C-terminal fragment — positions 11 through 13 — of α-melanocyte-stimulating hormone (α-MSH), retaining the parent hormone's anti-inflammatory activity through NF-κB pathway inhibition and cytokine modulation, without producing the pigmentation (melanotropic) effects of the full α-MSH molecule. The name is simply the single-letter amino acid code: K (lysine), P (proline), V (valine).

The tripeptide is derived from a specific portion of α-MSH, a 13-amino-acid neuropeptide with the sequence SYSMEHFRWGKPV. α-MSH itself is produced from the precursor protein proopiomelanocortin (POMC) through post-translational processing in the pituitary gland and other tissues. Research established that the anti-inflammatory activity of α-MSH resides substantially in its C-terminal three amino acids — the KPV fragment — while the pigmentation-inducing activity resides elsewhere in the molecule. This anatomical separation of function is what makes KPV research valuable: it isolates the anti-inflammatory activity from the pigmentation activity that limits full α-MSH research applications.

Beyond its origin, KPV has three defining characteristics. Its molecular formula is C16H30N4O4 with a molecular weight of approximately 342.4 Da (CAS: 30948-93-1) — small enough that it demonstrates unusual biological properties for a peptide, including oral bioavailability through the PepT1 intestinal transporter and stability in inflamed gastrointestinal tissue. Its mechanism operates through NF-κB pathway inhibition rather than receptor-level agonism. And its research applications span inflammatory bowel disease, wound healing, dermatological inflammation, and neuroinflammation contexts — a breadth that reflects the ubiquity of NF-κB-driven inflammation in mammalian biology.

The Discovery History

KPV's anti-inflammatory activity was first characterized by Michael E. Hiltz and James M. Lipton in a 1989 FASEB Journal paper that demonstrated the C-terminal tripeptide of α-MSH retained the parent molecule's anti-inflammatory action — a finding that established KPV as a distinct research compound and led to J.M. Lipton's foundational patents on the tripeptide in the early 1990s. Subsequent research expanded KPV's characterized activity across multiple inflammation models over the following three decades.

Why the discovery mattered

Before KPV was characterized as an independent bioactive compound, α-MSH's anti-inflammatory activity was known but limited in research utility by the parent molecule's pigmentation-inducing side effects. Hiltz and Lipton's 1989 demonstration that the C-terminal tripeptide retained the anti-inflammatory activity without the pigmentation effects (verified in the frog skin bioassay standard at the time) opened a new research direction: an anti-inflammatory peptide small enough to be synthesized cheaply, structurally simple enough to modify systematically, and biologically active enough to characterize in vitro and in vivo across multiple inflammation models.

Expansion into inflammatory bowel disease research

The most influential expansion of KPV's research profile came from Klaus Kannengiesser, Christian Maaser, and colleagues in a landmark 2008 Inflammatory Bowel Diseases journal paper. The paper demonstrated that oral KPV administration reduced intestinal inflammation in two established murine IBD models — DSS colitis and CD45RB(hi) transfer colitis — and identified the PepT1 peptide transporter as the mechanism by which KPV crosses the intestinal epithelium to reach sites of inflammation. This work established KPV as a reference tripeptide in IBD research and remains one of the most-cited KPV publications. Peer-reviewed research on KPV is searchable through PubMed KPV tripeptide research.

Ongoing research expansion

Subsequent research has expanded KPV's characterized activity into dermatological inflammation (psoriasis, dermatitis, and inflammatory acne models), wound healing (topical KPV in excisional wound models shows 20-30% faster wound closure), traumatic brain injury (Holloway et al. 2013 demonstrated attenuated brain damage after single-dose administration in a controlled cortical impact model), and antimicrobial research. The compound has become a standard reference tripeptide across NF-κB-mediated inflammation research.

How KPV Works: The NF-κB Inhibition Mechanism

KPV's primary mechanism is inhibition of the NF-κB (nuclear factor kappa B) transcription factor pathway — a central inflammatory signaling cascade in mammalian cells — with downstream effects including suppression of TNF-α, IL-6, and nitric oxide production, alongside induction of the anti-inflammatory cytokine IL-10. This mechanism operates without requiring receptor-level agonism, making KPV distinct from most other anti-inflammatory research peptides.

The NF-κB pathway

NF-κB is the master transcription factor that drives expression of most inflammatory response genes in mammalian cells. When cells receive inflammatory signals — TNF-α, LPS bacterial components, oxidative stress, tissue damage — NF-κB translocates from the cytoplasm to the nucleus and activates transcription of pro-inflammatory cytokines, adhesion molecules, and enzymes. KPV interferes with this activation, reducing the transcriptional output of the pro-inflammatory program. Published cellular research has documented KPV-mediated inhibition of TNF-α-stimulated NF-κB activation in keratinocytes, intestinal epithelial cells, macrophages, and dendritic cells.

Cytokine modulation

Beyond direct NF-κB inhibition, KPV modulates downstream cytokine production. Published preclinical work has measured reductions in TNF-α, IL-6, and nitric oxide following KPV exposure in models of inflammation, alongside induction of IL-10 — one of the primary anti-inflammatory cytokines involved in resolving inflammatory responses. This combination (suppression of pro-inflammatory cytokines plus induction of anti-inflammatory cytokines) shifts the immune balance toward resolution rather than perpetuation of inflammation.

The PepT1 transporter mechanism

KPV's oral bioavailability in gut inflammation models is unusual for a peptide, since most peptides are hydrolyzed by gastrointestinal proteases before absorption. The mechanism involves the PepT1 peptide transporter, which is upregulated in inflamed intestinal epithelium. Oral KPV crosses inflamed gut mucosa through PepT1-mediated transport, reaching sites of inflammation directly. This tissue-specific delivery — where KPV is preferentially taken up at inflamed sites rather than distributed systemically — is one of the mechanistic features that makes KPV particularly relevant to inflammatory bowel disease research.

Current Regulatory Landscape (2026 Update)

KPV's regulatory status in the United States shifted significantly in 2026 — the FDA removed KPV from Category 2 (compounding-restricted) on April 22, 2026, and the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed KPV for inclusion on the Section 503A Bulk Drug Substances List on July 23, 2026, with the committee voting favorably. This represents the most significant regulatory activity for KPV in more than a decade, though final FDA action remains pending as of August 2026.

The 2026 regulatory context

In 2023, the FDA had categorized KPV alongside a group of research peptides (including BPC-157, TB-500, and MOTS-c) as Category 2 substances under its compounding framework, citing an absence of human exposure data and limited safety characterization. That decision significantly narrowed patient access to KPV through licensed compounding channels in the United States. In early 2026, following broader policy shifts around peptide compounding restrictions, the FDA announced the PCAC would formally evaluate KPV and other peptides for possible addition to the Section 503A Bulks List.

What the 2026 review outcome means

The July 23, 2026 PCAC vote was a favorable recommendation for KPV's inclusion on the Section 503A Bulks List, but a committee recommendation is not the same as FDA approval. The FDA retains final decision authority, and formal regulatory action remains pending. What the review process does establish is that KPV is under active regulatory consideration — a significant shift from the 2023 restrictive categorization. Regulatory documentation is available through the FDA Section 503A Bulk Drug Substances under Evaluation framework.

Canadian regulatory context

Health Canada has not approved KPV for any human or veterinary therapeutic use, and the FDA regulatory developments do not directly change Canadian regulatory status. For Canadian research laboratories, KPV remains available for laboratory research applications with the same research-use-only framework that applies to other investigational research peptides. The FDA activity is relevant primarily as context — it signals evolving international regulatory attention on the compound rather than any change in Canadian access.

Current Research Applications

KPV research applications cluster into four primary categories — inflammatory bowel disease and colitis research, wound healing and skin inflammation, neuroinflammation and traumatic brain injury models, and antimicrobial research. Each category exploits different aspects of KPV's characterized biology, from PepT1-mediated gut delivery to topical anti-inflammatory action to systemic immunomodulation.

Inflammatory bowel disease research

IBD research remains KPV's strongest published application category. DSS colitis and CD45RB(hi) transfer colitis models have consistently reported reductions in inflammatory markers, mucosal damage, and disease activity indices following KPV administration. Nanoparticle-formulated oral KPV has extended this research direction by improving targeted delivery to inflamed colon tissue. Research designs investigating ulcerative colitis, Crohn's disease models, and colitis-associated cancer prevention frequently use KPV as a reference anti-inflammatory tripeptide.

Wound healing and dermatological research

Topical KPV research has documented accelerated wound closure in excisional wound models — 20-30% faster wound area reduction compared to untreated controls in some rodent studies — through combined anti-inflammatory action and effects on keratinocyte migration. Research designs investigating psoriasis, dermatitis, inflammatory acne, and other NF-κB-driven skin conditions have used KPV in cellular models to characterize its anti-inflammatory activity in cutaneous tissue.

Neuroinflammation research

Holloway and colleagues published a 2013 study demonstrating that single-dose administration of α-MSH(11-13) attenuated brain damage in a murine controlled cortical impact traumatic brain injury model — reduced lesion volume, reduced inflammation, and reduced apoptosis in treated animals. This work extended KPV's research applications into CNS inflammation and traumatic brain injury research, where NF-κB-mediated inflammation contributes to secondary brain damage.

Antimicrobial research

KPV inherits antimicrobial activity from its parent α-MSH molecule, with published research documenting activity against various bacterial and fungal pathogens. This antimicrobial profile is particularly relevant in research contexts where pathogenic bacterial translocation contributes to inflammatory disease — for example, in IBD research where the dual anti-inflammatory and antimicrobial profile has combined research relevance.

How KPV Fits Within Emerald Peptides' Catalog

KPV occupies a research niche distinct from most of Emerald Peptides' catalog — it's an anti-inflammatory tripeptide that complements rather than duplicates our recovery, metabolic, and longevity peptides. Understanding how KPV combines with other compounds clarifies its research applications.

KPV pairs naturally with BPC-157 in gastrointestinal repair research, where BPC-157's cytoprotection and angiogenesis effects combine with KPV's anti-inflammatory action for multi-mechanism gut mucosa research. KPV also pairs with GHK-Cu in dermatological inflammation research, where GHK-Cu's ECM remodeling combines with KPV's anti-inflammatory action for skin repair investigations.

Our KLOW Stack integrates KPV alongside BPC-157, TB-500, and GHK-Cu into a matched-batch research kit for multi-mechanism regenerative research designs that need parallel-pathway coverage of tissue repair, inflammation modulation, and extracellular matrix remodeling simultaneously. For research designs investigating tissue repair without the inflammatory modulation KPV provides, the Wolverine Stack and Glow Stack offer subsets of the KLOW Stack's compound coverage.

For broader coverage of tissue repair and inflammation research in Canadian laboratories, see Best Peptides for Recovery Research: A Comparison Guide for Canadian Labs.

Sourcing Considerations

Research-grade KPV should meet four sourcing criteria: ≥99% HPLC purity, mass spectrometry identity confirmation matching the 342.4 Da theoretical molecular weight, batch-specific certificates of analysis, and Canadian domestic supply chain integrity for reliable cold-chain shipping. KPV's short structure makes it relatively easy to synthesize, but supplier quality variance remains substantial.

The molecular weight signature for MS verification is straightforward — approximately 342.4 Da for the three-amino-acid tripeptide with the specific sequence K-P-V (Lys-Pro-Val). Suppliers who cannot provide MS-verified identity documentation introduce unnecessary compound identity risk, particularly given the number of low-quality vendors that have entered the KPV market following the 2026 regulatory activity. For a broader framework on supplier evaluation, see Emerald Peptides vs. Other Brands: 7 Standards That Separate Quality Research Peptide Suppliers. Peer-reviewed research on peptide analytical quality standards is available through PubMed peptide analytical research.

Frequently Asked Questions

What does KPV stand for?

KPV stands for the three amino acids that comprise the peptide — lysine (K), proline (P), and valine (V). It corresponds to positions 11 through 13 (the C-terminal three amino acids) of α-melanocyte-stimulating hormone, a 13-amino-acid neuropeptide. KPV is also written as α-MSH(11-13) in scientific literature. The tripeptide was first characterized as an independent anti-inflammatory compound by Hiltz and Lipton in 1989.

What is KPV used for in research?

KPV is used primarily in four research application categories: inflammatory bowel disease and colitis research (where DSS and CD45RB colitis models have documented reduced inflammatory markers following KPV administration); wound healing and skin inflammation research (where topical KPV has shown accelerated wound closure and reduced dermal inflammation); neuroinflammation research (where single-dose administration has demonstrated attenuated brain damage in traumatic brain injury models); and antimicrobial research (where KPV retains antimicrobial activity from its parent α-MSH molecule).

How is KPV different from α-MSH?

KPV and α-MSH share anti-inflammatory activity, but α-MSH is a 13-amino-acid peptide that also produces melanotropic (pigmentation) effects through its N-terminal region. KPV corresponds to only the C-terminal three amino acids (positions 11-13) — the portion responsible for anti-inflammatory activity — and does not produce pigmentation effects. This anatomical separation of function makes KPV particularly useful in research designs where anti-inflammatory investigation must be separated from melanotropic confounders. Additionally, KPV's smaller size provides oral bioavailability advantages through PepT1-mediated intestinal transport that full α-MSH lacks.

Is KPV approved for human use?

No. KPV is not approved by Health Canada, the FDA, or any regulatory agency for human therapeutic use. However, KPV's regulatory status in the United States shifted in 2026 — the FDA removed KPV from Category 2 (compounding-restricted) on April 22, 2026, and the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted favorably on including KPV on the Section 503A Bulk Drug Substances List on July 23, 2026. Final FDA action remains pending. For Canadian research laboratories, KPV remains available for laboratory research applications under the research-use-only framework.

How does KPV work mechanistically?

KPV's primary mechanism is inhibition of the NF-κB (nuclear factor kappa B) transcription factor pathway — a central inflammatory signaling cascade in mammalian cells. This inhibition reduces production of TNF-α, IL-6, and nitric oxide while inducing the anti-inflammatory cytokine IL-10. KPV also demonstrates unusual oral bioavailability through PepT1 peptide transporter-mediated absorption in inflamed intestinal epithelium, which enables tissue-specific delivery to sites of inflammation. Together, these mechanisms give KPV its characterized anti-inflammatory activity across multiple tissue types.

Where can researchers buy KPV in Canada?

Research-grade KPV is available through Canadian research peptide suppliers who meet HPLC purity, mass spectrometry identity, and batch documentation standards. Our KPV research peptide is supplied at ≥99% HPLC purity with MS-verified identity, batch-specific COAs, and fast domestic Canadian shipping. All vials are sold strictly for laboratory research use only. Researchers requiring multi-mechanism regenerative research kits containing KPV alongside other compounds can also source our KLOW Stack.

⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.